Fight CRC Clinical Trial Finder
NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT03638206 |
TitleAutologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | Phase
Phase 1/Phase 2
|
Date Added 2018-08-20 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
CAR-T cell immunotherapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03772561 |
TitlePhase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies | Phase
Phase 1
|
Date Added 2018-12-11 |
Location
Singapore
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
AZD5363+Olaparib+Durvalumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT02343991 |
TitleBlood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound | Phase
Not Applicable
|
Date Added 2015-01-22 |
Location
Canada
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Transcranial ExABlate |
Tags
MSS/ MMRp
|
NCT ID NCT04991948 |
TitleStudy of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2021-08-05 |
Location
Florida, United States
Belgium |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
CYAD-101, FOLFOX, Pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05299840 |
TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer | Phase
Not Applicable
|
Date Added 2022-03-29 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03865082 |
TitleStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Phase
Phase 2
|
Date Added 2019-03-06 |
Location
Arizona, United States
California, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab, Tilsotolimod, Opdivo, Yervoy |
Tags
MSS/ MMRp
|
NCT ID NCT03366155 |
TitleHepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | Phase
Phase 2
|
Date Added 2017-12-08 |
Location
Maryland, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
5FU, cetuximab, FUDR-Dex, Irinotecan, Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter, OneRNA, oxaliplatin, panitumumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03297606 |
TitleCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Phase
Phase 2
|
Date Added 2017-09-29 |
Location
Canada
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temsirolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03488953 |
TitleLiving Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases | Phase
Not Applicable
|
Date Added 2018-04-05 |
Location
Germany
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT04660812 |
TitleAn Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | Phase
Phase 1, Phase 2
|
Date Added 2020-12-09 |
Location
Alabama, United States
Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States France Italy Korea, Republic of Spain United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab |
Tags
MSS/ MMRp
|